Retension Pharmaceuticals Inc. (RTSN:NASDAQ) closed at $11.04 on November 6, 2026, up 2.99% on the day. The stock trades 40.8% below its 52-week high of $18.64 and 14.3% above its 52-week low of $9.66. Over the past year, it gained 4.8%. Retension Pharmaceuticals Inc. is part of the Health Care sector.
In 20 trading sessions since October 12, 2026, RTSN closed higher on 9 days (45%). Its best day was October 19, 2026 (+16.06%) and its worst was October 29, 2026 (-9.63%). The stock moved 10% or more in a single session 2 times.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company's lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
Find more stocks like RTSN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.